Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Abstract

Described herein are crystalline forms of compounds that are deoxycytidine kinase (dCK) inhibitors, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of using such crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of deoxycytidine kinase (dCK) activity.

1 - 96 . (canceled) 
     
     
         97 . A method of treating an autoimmune disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is administered once daily. 
       
     
     
         98 . The method of  claim 97 , wherein the disease or disorder is multiple sclerosis. 
     
     
         99 . The method of  claim 97 , wherein the disease or disorder is optic neuritis. 
     
     
         100 . The method of  claim 97 , wherein the disease or disorder is acute disseminated encephalomyelitis (ADEM). 
     
     
         101 - 113 . (canceled) 
     
     
         114 . The method of  claim 97 , wherein the compound of Formula I is formulated for oral administration. 
     
     
         115 . The method of  claim 97 , wherein the compound of Formula I is formulated as a tablet, a pill, a capsule, a powder, a liquid, a suspension, a solution, a suppository, or an aerosol. 
     
     
         116 . The method of  claim 97 , wherein the compound of Formula I is formulated as a solution. 
     
     
         117 - 120 . (canceled) 
     
     
         121 . The method of  claim 97 , wherein the administration of the compound of Formula I results in a decrease in interferon gamma (IFNγ) levels in the subject. 
     
     
         122 . The method of  claim 121 , wherein the decrease in IFNγ levels determined in a fluid sample of the subject. 
     
     
         123 . The method of  claim 122 , wherein the fluid comprises plasma. 
     
     
         124 . The method of  claim 97 , wherein the administration of the compound of Formula I results in a decrease in the severity of the disease or disorder, relative to a control. 
     
     
         125 . The method of  claim 124 , wherein the severity of the disease or disorder is assessed by a numerical scoring system. 
     
     
         126 . The method of  claim 97 , wherein the administration of the compound of Formula I results in a decrease in limb weakness in the subject, relative to a control. 
     
     
         127 . The method of  claim 97 , wherein the administration of the compound of Formula I results in a decreased risk of paralysis in the subject, relative to a control subject. 
     
     
         128 . The method of  claim 97 , wherein the administration of the compound of Formula I prevents or decreases a reduction in body weight in subject. 
     
     
         129 . The method of  claim 97 , wherein the administration of the compound of Formula I prevents or decreases a reduction in an organ weight in subject. 
     
     
         130 . The method of  claim 129 , wherein the organ comprises bone, muscle, or spleen. 
     
     
         131 . The method of  claim 97 , wherein the compound of Formula I is formulated as a tablet, a pill, a capsule, or a powder. 
     
     
         132 . The method of  claim 131 , wherein the tablet, pill, capsule, or powder is administered orally to the subject. 
     
     
         133 . The method of  claim 97 , wherein the subject is a mammal.